CO2021017619A2 - Moduladores del receptor alfa relacionado con estrógeno (errα) - Google Patents
Moduladores del receptor alfa relacionado con estrógeno (errα)Info
- Publication number
- CO2021017619A2 CO2021017619A2 CONC2021/0017619A CO2021017619A CO2021017619A2 CO 2021017619 A2 CO2021017619 A2 CO 2021017619A2 CO 2021017619 A CO2021017619 A CO 2021017619A CO 2021017619 A2 CO2021017619 A2 CO 2021017619A2
- Authority
- CO
- Colombia
- Prior art keywords
- errα
- modulators
- receptor alpha
- estrogen
- related receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184515 | 2019-07-04 | ||
| PCT/EP2020/068574 WO2021001453A1 (en) | 2019-07-04 | 2020-07-01 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021017619A2 true CO2021017619A2 (es) | 2022-04-19 |
Family
ID=67180693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0017619A CO2021017619A2 (es) | 2019-07-04 | 2021-12-21 | Moduladores del receptor alfa relacionado con estrógeno (errα) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12527774B2 (https=) |
| EP (1) | EP3994138B1 (https=) |
| JP (1) | JP7606479B2 (https=) |
| KR (1) | KR20220029719A (https=) |
| CN (1) | CN114341135B (https=) |
| AR (1) | AR119348A1 (https=) |
| AU (1) | AU2020298779A1 (https=) |
| BR (1) | BR112021026687A2 (https=) |
| CO (1) | CO2021017619A2 (https=) |
| ES (1) | ES3032908T3 (https=) |
| IL (1) | IL289510B2 (https=) |
| MA (1) | MA56444A (https=) |
| MX (1) | MX2022000165A (https=) |
| PH (1) | PH12021553204A1 (https=) |
| UA (1) | UA129204C2 (https=) |
| WO (1) | WO2021001453A1 (https=) |
| ZA (1) | ZA202200591B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023011456A1 (en) * | 2021-08-03 | 2023-02-09 | Beigene, Ltd. | Pyrazolopyridinone compounds |
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA016887B1 (ru) * | 2007-03-07 | 2012-08-30 | Янссен Фармацевтика Н.В. | ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α |
| NZ579372A (en) | 2007-03-07 | 2012-02-24 | Janssen Pharmaceutica Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| CN103288823B (zh) * | 2012-02-23 | 2015-02-18 | 华东理工大学 | N,n’-芳基取代脲类化合物及其用途 |
| CN104119285B (zh) | 2013-04-28 | 2016-06-29 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| KR101819639B1 (ko) * | 2016-06-27 | 2018-01-17 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
-
2020
- 2020-07-01 BR BR112021026687A patent/BR112021026687A2/pt unknown
- 2020-07-01 KR KR1020227003499A patent/KR20220029719A/ko active Pending
- 2020-07-01 MX MX2022000165A patent/MX2022000165A/es unknown
- 2020-07-01 EP EP20735186.7A patent/EP3994138B1/en active Active
- 2020-07-01 US US17/624,297 patent/US12527774B2/en active Active
- 2020-07-01 ES ES20735186T patent/ES3032908T3/es active Active
- 2020-07-01 PH PH1/2021/553204A patent/PH12021553204A1/en unknown
- 2020-07-01 JP JP2021577993A patent/JP7606479B2/ja active Active
- 2020-07-01 CN CN202080062286.XA patent/CN114341135B/zh active Active
- 2020-07-01 MA MA056444A patent/MA56444A/fr unknown
- 2020-07-01 WO PCT/EP2020/068574 patent/WO2021001453A1/en not_active Ceased
- 2020-07-01 AU AU2020298779A patent/AU2020298779A1/en active Pending
- 2020-07-01 UA UAA202200271A patent/UA129204C2/uk unknown
- 2020-07-01 IL IL289510A patent/IL289510B2/en unknown
- 2020-07-03 AR ARP200101889A patent/AR119348A1/es unknown
-
2021
- 2021-12-21 CO CONC2021/0017619A patent/CO2021017619A2/es unknown
-
2022
- 2022-01-12 ZA ZA2022/00591A patent/ZA202200591B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL289510A (en) | 2022-03-01 |
| ES3032908T3 (en) | 2025-07-28 |
| MA56444A (fr) | 2022-05-11 |
| AR119348A1 (es) | 2021-12-09 |
| JP2022538363A (ja) | 2022-09-01 |
| IL289510B2 (en) | 2025-08-01 |
| PH12021553204A1 (en) | 2022-11-07 |
| JP7606479B2 (ja) | 2024-12-25 |
| US20220387401A1 (en) | 2022-12-08 |
| CN114341135B (zh) | 2025-03-18 |
| EP3994138B1 (en) | 2025-04-02 |
| US20250268872A2 (en) | 2025-08-28 |
| UA129204C2 (uk) | 2025-02-05 |
| US12527774B2 (en) | 2026-01-20 |
| KR20220029719A (ko) | 2022-03-08 |
| IL289510B1 (en) | 2025-04-01 |
| MX2022000165A (es) | 2022-05-20 |
| ZA202200591B (en) | 2023-07-26 |
| EP3994138C0 (en) | 2025-04-02 |
| AU2020298779A1 (en) | 2022-02-17 |
| CN114341135A (zh) | 2022-04-12 |
| BR112021026687A2 (pt) | 2022-03-08 |
| CA3144891A1 (en) | 2021-01-07 |
| EP3994138A1 (en) | 2022-05-11 |
| WO2021001453A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017619A2 (es) | Moduladores del receptor alfa relacionado con estrógeno (errα) | |
| CO2022003829A2 (es) | Moduladores de receptor alfa relacionado con estrógenos (errα) | |
| CO2021008998A2 (es) | Amidas de pirrolidina iii sustituidas | |
| CO6470866A2 (es) | Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos. | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2015010935A (es) | Compuestos biciclicos antidiabeticos. | |
| ECSP12011983A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
| CL2021000126A1 (es) | Derivados de triazolquinoxalina adicionalmente sustituidos | |
| MX374728B (es) | MODULADORES DE ROR GAMMA (RORy). | |
| CL2020003074A1 (es) | Inhibidores de la vía de respuesta al estrés integrada. | |
| MX2014003334A (es) | Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos. | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| MX2022007670A (es) | Compuestos antihelminticos que comprenden una estructura de quinolina. | |
| UY32858A (es) | Derivados de (tio)morfolina como moduladores de sip | |
| MX377329B (es) | Moduladores de ror gamma (ror?). | |
| MX378111B (es) | Moduladores de ror gamma (ror?). | |
| MX2021015873A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. | |
| MX386293B (es) | Compuestos de aminoindano y su uso en el tratamiento del dolor. | |
| CO2020016131A2 (es) | Agonistas de tlr7 | |
| DOP2016000311A (es) | Nuevos compuestos | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| DOP2019000119A (es) | Moduladores de ROR gamma (RORy) | |
| ECSP11010795A (es) | Compuestos de fenantrenona, composiciones y métodos | |
| AR131577A1 (es) | Compuestos moduladores del receptor de dopamina d3 / d2 | |
| AR133581A1 (es) | Heterociclos bicíclicos como antagonistas de mrgprx2 |